Phathom Pharmaceuticals, Inc.
PHAT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $49,504 | $39,503 | $28,519 | $29,664 |
| % Growth | 25.3% | 38.5% | -3.9% | – |
| Cost of Goods Sold | $6,190 | $5,038 | $3,724 | $3,815 |
| Gross Profit | $43,314 | $34,465 | $24,795 | $25,849 |
| % Margin | 87.5% | 87.2% | 86.9% | 87.1% |
| R&D Expenses | $7,027 | $9,076 | $9,184 | $8,583 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $51,558 | $85,313 | $94,474 | $76,683 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $58,585 | $94,389 | $103,658 | $85,266 |
| Operating Income | -$15,271 | -$59,924 | -$78,863 | -$59,417 |
| % Margin | -30.8% | -151.7% | -276.5% | -200.3% |
| Other Income/Exp. Net | -$14,702 | -$15,886 | -$15,453 | -$15,034 |
| Pre-Tax Income | -$29,973 | -$75,810 | -$94,316 | -$74,451 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$29,973 | -$75,810 | -$94,316 | -$74,451 |
| % Margin | -60.5% | -191.9% | -330.7% | -251% |
| EPS | -0.41 | -1.05 | -1.31 | -1.05 |
| % Growth | 61% | 19.8% | -24.8% | – |
| EPS Diluted | -0.41 | -1.05 | -1.31 | -1.05 |
| Weighted Avg Shares Out | 73,396 | 72,466 | 71,969 | 71,045 |
| Weighted Avg Shares Out Dil | 73,396 | 72,466 | 71,969 | 71,045 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,413 | $1,787 | $2,640 | $3,510 |
| Interest Expense | $16,108 | $17,518 | $18,071 | $18,593 |
| Depreciation & Amortization | $156 | $172 | $177 | $193 |
| EBITDA | -$13,709 | -$58,120 | -$76,068 | -$55,665 |
| % Margin | -27.7% | -147.1% | -266.7% | -187.7% |